Consider running retatrutide as monotherapy at its full dose range first, as the triple agonist alone produces excellent results
Laboratory research record on Glow | GHK-CU, TB-500, BPC-157 Blend [PMID: 34572392] PubMed laboratory record discussing Glow | GHK-CU, TB-500, BPC-157 Blend in a research context
Multiple clinical trials and controlled studies have demonstrated: Statistically significant improvements in skin firmness and elasticity with consistent use Reduction in fine lines and wrinkle depth over 3-6 months of application Improved skin density, moisture retention, and surface texture Reduction in photodamage and hyperpigmentation Tightening of loose skin documented in both topical and injectable applications Citation: Leyden JJ et al
Even though, considering the essentiality of copper in humans, the copper hypothesis of GHK mechanism of action seems very attractive, recent gene data may challenge this mechanism and demand more studies into GHKs mechanism of action
Gene expression breadth: Pickart and Margolina (2018) analyzed GHK against the Connectivity Map database and reported effects on gene sets associated with inflammation, DNA repair, ubiquitin-proteasome pathways, and mitochondrial function, spanning more than 4,000 genes in their analysis